4D-125 for XLRP, 4D-150 for wet AMD, 4D-710 for cystic fibrosis and 4D-110 for choroideremia. Schiffmann has published 276 peer-reviewed research articles and over 15 book chapters. To access the live call by phone, dial (833) 540-1164 (domestic) or (929) 517-0354 (international). One of his particular interests and areas of expertise is to address patients with undiagnosed neurological diseases. Schiffmann has been performing pre-clinical and clinical research on lysosomal storage diseases since 1991 with a special focus on the natural history, pathogenesis and therapy of Fabry disease, Gaucher disease and the leukodystrophies. Angelique Mittan, CLS Senior Director, Clinical Operations at 4D Molecular Therapeutics Danville, California, United States 571 followers 500+ connections Join to view profile 4D. He is also a Senior Vice President for Clinical Research at 4D Molecular Therapeutics.ĭr. Consultant: 4D Molecular Therapeutics Adverum Biotechnologies, Inc. Schiffmann is a Professor in the Department of Internal Medicine, Texas Christian University and a Clinical Professor, Texas A&M University Medical School College of Medicine. For questions regarding CME credit, contact the Paradigm CME Department at. Schiffmann was a lead researcher at the United States National Institutes of Health in Bethesda, Maryland for over 17 years (1991-2007) and then the Director of the Institute of Metabolic Disease at the Baylor Scott & White Research Institute in Dallas, Texas, 2008-2019. He is Board certified in Neurology with a Special Qualification in Child Neurology, and is a Fellow of the American Academy of Neurology.ĭr. He earned his medical degree from the University of Liège, Belgium and a degree of Master of Health Sciences in Clinical Research from Duke University. Schiffmann is a renowned expert on neurometabolic diseases. 4D Molecular Therapeutics is headquartered at Emeryville, California, the US.įor a complete picture of 4D-110’s drug-specific PTSR and LoA scores, buy the report here.Dr. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced interim clinical data from cohort 1 of the Phase 1/2 clinical trial of intravitreal 4D-150 for wet AMD. Hoffmann-La Roche Ltd to design, develop and commercialize AAV products for use in ophthalmology indications. 14, 2022 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics, Inc. 4D Molecular Therapeutics develops pipeline products that targets therapeutic areas such as liver, retina, heart, brain, skeletal muscle, and lung, among others. It has developed a technology platform, Therapeutic Vector Evolution that empowers to create customized gene delivery vehicles (novel AAV vectors) to deliver genes to any tissue or organ in the body. The therapy is based on vector evolution platform technology that uses AAV2 (Adeno-Associated Virus2) vector variant carrying a transgene encoding a codon-optimized human choroideremia (CHM) gene.ĤD Molecular Therapeutics is a gene therapy company that discovers and develops targeted and proprietary AAV gene therapy vectors and therapeutic products. The therapy is administered through intravitreal route into retina. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.ĤD-110 is under development for the treatment of choroideremia. 4D Molecular Therapeutics overview 4D Molecular Therapeutics is a gene therapy company that discovers and develops targeted and proprietary AAV gene therapy vectors and therapeutic products. SVB Securities analyst Mani Foroohar maintained a Hold rating on 4D Molecular Therapeutics ( FDMT Research Report) yesterday. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |